Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model

Documenti analoghi

• The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
  di: Phil McEwan, et al.
  Pubblicazione: (2025)
• Association between glycated haemoglobin A 1c and total haemoglobin mass in adults with type 1 diabetes mellitus. A proof‐of‐concept study
  di: Janis Schierbauer, et al.
  Pubblicazione: (2025)
• Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada
  di: Tina Kim, et al.
  Pubblicazione: (2024)
• Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability
  di: Johnny T. K. Cheung, et al.
  Pubblicazione: (2024)
• Change in glycated haemoglobin in adults with type 2 diabetes on basal‐bolus insulin regimens following commencement of Freestyle Libre use
  di: Anna R. Dover, et al.
  Pubblicazione: (2024)